Sep 2026· Journal of Surgical Oncology· Vol 134, pp. 631 - 638· 0 citations· 36 references
Medicine
TL;DR
It is hypothesized that tumor response to different neoadjuvant approaches reflects underlying tumor biology, and achieving a pathologic complete response (pCR) with single‐agent neoadjuvant may signal favorable biology.
Abstract
Neoadjuvant therapy for pancreatic adenocarcinoma (PDAC) has evolved from single‐agent to multi‐agent approaches, largely informed by metastatic disease studies demonstrating improved survival; albeit at the price of increased toxicity. It remains unclear how response to varied neoadjuvant regimens impact survival. We hypothesized that tumor response to different neoadjuvant approaches reflects underlying tumor biology, and achieving a pathologic complete response (pCR) with single‐agent neoadjuvant may signal favorable biology.
The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage, and seven trials addressing these dimensions may collectively redefine PDAC treatment.
V. Groot, I. Molenaar, G. Cirkel et al.· i Medicina· 0 citations
Pancreatic cancer (PC) is on the rise worldwide, with significant improvements in survival rates still awaited. Most patients are diagnosed at an advanced stage, often with liver metastases (LM), associated with poor prognosis and immunosuppression. This study aimed to evaluate the impact of LM on outcomes in patients...
L. Kjær, S. Theile, K. Madsen et al.· Immunity, Inflammation and D...· 0 citations
In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy...
Zhen-Yan Wang, Yan Wang· Clinical Case Reports· 1 citation
Trials show that ivonescimab combined with chemotherapy improved overall survival, and sunvozertinib improved progression‐free survival, and ivonescimab combined with chemotherapy improved overall survival.
Glioblastoma (GBM) remains highly morbid despite maximal safe resection, radiotherapy, and chemotherapy, prompting the expansion of clinical investigation. This review examines 4 emerging therapeutic strategies for newly diagnosed and recurrent GBM that address major biological barriers to treatment: tumor immunosuppre...
Deveney Franklin, D. Higgins· Hematology/Oncology Clinics...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
